<?xml version="1.0" encoding="UTF-8"?><REUTERS CGISPLIT="TRAINING-SET" LEWISSPLIT="TRAIN" NEWID="4912" OLDID="9825" TOPICS="YES">
<DATE>13-MAR-1987 13:08:43.78</DATE>
<TOPICS/>
<PLACES><D>usa</D></PLACES>
<PEOPLE/>
<ORGS/>
<EXCHANGES/>
<COMPANIES/>
<UNKNOWN> 
   A RM
   f0825 reute
r f BC-LYPHOMED-&lt;LMED&gt;-SELLS   03-13 0094</UNKNOWN>
<TEXT> 
<TITLE>LYPHOMED &lt;LMED&gt; SELLS CONVERTIBLE DEBENTURES</TITLE>
<DATELINE>    NEW YORK, March 13 - </DATELINE><BODY>LyphoMed Inc is raising 70 mln dlrs
through an offering of convertible subordinatred debentures due
2012 with a 5-1/2 pct coupon and par pricing, said lead manager
Alex Brown and Sons Inc.
    The debentures are convertible into the company's common
stock at 36.25 dlrs per share, representing a premium of 27.75
pct over the stock price when terms on the debt were set.
    Non-callable for two years, the issue is rated BB by
Standard and Poor's Corp. Montgomery Securities co-managed the
deal.
 Reuter
 </BODY></TEXT>
</REUTERS>